Amiodarone RLP Episode 014

Amiodarone serves as a class 3 antiarrhythmic primarily utilized for rhythm control in atrial fibrillation when initial rate control strategies fail. Its complex mechanism involves sodium, potassium, and calcium channel blockade, alongside mild alpha and beta-blocking activity. A defining characteristic is its exceptionally long half-life of 40 to 60 days, which complicates drug interactions and extends the duration of adverse effects. Clinical management requires vigilant monitoring due to significant risks, including a black box warning for pulmonary fibrosis and potential liver toxicity. Furthermore, amiodarone frequently induces hypothyroidism and interacts dangerously with other medications; it can double digoxin levels through P-glycoprotein inhibition and increase rhabdomyolysis risk when combined with 3A4-metabolized statins like simvastatin. Concurrent use with QTc-prolonging agents, such as fluoroquinolones or citalopram, further elevates the risk of life-threatening Torsades de Pointes.